{
    "root": "2f3607c9-6e93-1171-e063-6294a90a2407",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ONAPGO",
    "value": "20250228",
    "ingredients": [
        {
            "name": "SODIUM METABISULFITE",
            "code": "4VON5FNS3C"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "APOMORPHINE HYDROCHLORIDE",
            "code": "F39049Y068"
        }
    ],
    "indications": "onapgo indicated treatment motor fluctuations adults advanced parkinson 's disease .",
    "contraindications": "subcutaneous infusion . ( 2.1 ) maximum recommended total daily onapgo , including continuous extra dose ( ) , 98 mg generally administered waking day ( e.g . , 16 hours ) . ( 2.3 ) recommended initial continuous 1 mg/hr maximum 6 mg/hr 16 hours per day . ( 2.3 ) extra dose may titrated increments 0.5 mg 1 mg based response tolerability . subsequent extra doses 0.5 mg 2 mg , least 3 hours extra doses maximum 3 extra doses per day . ( 2.3 ) treatment trimethobenzamide recommended , starting 3 days prior first dose onapgo , continued long necessary control nausea vomiting , generally longer two months . ( 2.2 , 5.2 , 6.1 , 17 ) onapgo substitutable apomorphine products intended intermittent . ( 2.3 ) patients mild moderate renal impairment , recommended initial extra dose 0.5 mg 1 mg exceed 1 mg. ( 2.5 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "onapgo contraindicated patients : using concomitant 5ht 3antagonists , including antiemetics ( e.g . , ondansetron , granisetron , dolasetron , palonosetron ) alosetron [ ( 7.1 ) ] . reports profound hypotension loss consciousness apomorphine administered ondansetron . hypersensitivity/allergic reaction apomorphine excipients onapgo , including sulfite ( i.e . , sodium metabisulfite ) . angioedema anaphylaxis may occur [ ( 5.13 ) ] .",
    "indications_original": "ONAPGO is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease.",
    "contraindications_original": "For subcutaneous use by infusion only. ( 2.1 ) Maximum recommended total daily dosage of ONAPGO, including the continuous dosage and any extra dose(s), is 98 mg generally administered over the waking day (e.g., 16 hours). ( 2.3 ) The recommended initial continuous dosage is 1 mg/hr with a maximum of 6 mg/hr for up to 16 hours per day. ( 2.3 ) The extra dose may be titrated in increments of 0.5 mg or 1 mg based on clinical response and tolerability. Subsequent extra doses are between 0.5 mg and 2 mg, with at least 3 hours between extra doses and a maximum of 3 extra doses per day. ( 2.3 ) Treatment with trimethobenzamide is recommended, starting 3 days prior to the first dose of ONAPGO, and should only be continued as long as necessary to control nausea and vomiting, and generally no longer than two months. ( 2.2 , 5.2 , 6.1 , 17 ) ONAPGO is not substitutable for apomorphine products intended for intermittent use. ( 2.3 ) For patients with mild or moderate renal impairment, the recommended initial extra dose is 0.5 mg to 1 mg and should not exceed 1 mg. ( 2.5 )",
    "adverseReactions_original": "ONAPGO is contraindicated in patients:\n                  \n                     Using concomitant 5HT\n  \n   3antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron\n  \n   [see\n   \n    Drug Interactions (7.1)]\n  \n   . There have been reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron.\n \n  \n                     With hypersensitivity/allergic reaction to apomorphine or any of the excipients of ONAPGO, including sulfite (i.e., sodium metabisulfite). Angioedema or anaphylaxis may occur\n  \n   [see\n   \n    Warnings and Precautions (5.13)]."
}